<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332445</url>
  </required_header>
  <id_info>
    <org_study_id>HB032-19</org_study_id>
    <nct_id>NCT04332445</nct_id>
  </id_info>
  <brief_title>Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.</brief_title>
  <official_title>Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbarium Laboratorio Botanico Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herbarium Laboratorio Botanico Ltda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study for health care product safety assessment. The research is going to
      conducted with 55 subjects, aged 18 to 70 years. The product is applied on the right and/or
      left participant back. After a wash out, the product is reapplied. Medical evaluation will be
      available throughout the study to assess possible adverse events. The main of the study is to
      observe the effects of the application of the product on the skin and prove the absence of
      irritability and/or allergy, photoallergy and phototoxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects phototypes I to IV (according to Fitzpatrick classification). The products is
      applied over semi-occlusive dressings, remaing in contact with the skin.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Clinical trial, single-arm</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythema degree or absence</measure>
    <time_frame>39 days</time_frame>
    <description>Erythema evaluation according to International Contact Dermatitis Research Group</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Sensitivity, Contact</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects, 18-70 y, healthy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyaluronic Acid Gel</intervention_name>
    <description>Health care product - to be apllied on the subject`s skin</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants;

          -  Non-injured skin in the test region;

          -  Agreement to adhere to the test procedures and requirements and to attend the
             institute on the day(s) and at the time(s) determined for the evaluations;

          -  Ability to consent to participation in the study;

          -  Phototype (Fitzpatrick): II and III;

        Exclusion Criteria:

          -  Pregnant or breastfeeding women;

          -  Use of the following systemic drugs: antihistamines, non-hormonal anti-inflammatory
             drugs and corticoids;

          -  History of allergy to cosmetics, topical products or research product;

          -  Localized or widespread dermatological diseases or inflammatory dermatoses active and
             nerve damage in the test region;

          -  Personal or family pathological history of skin cancer;

          -  Use of topical or systemic photosensitizing medication;

          -  History of phototoxic, photoallergic reactions, dermatoses caused by light, atopy,
             pathologies aggravated or triggered by ultraviolet radiation;

          -  Photo-induced pathologies;

          -  Frequent exposure to the sun or tanning chambers;

          -  Participated in an allergenicity study in a period of less than 4 weeks from the start
             of the study;

          -  Skin marks in the experimental area that interfere with the evaluation of possible
             reactions;

          -  Active dermatoses;

          -  Forecast to take a bath in the sea, pool or sauna during the study;

          -  Participants who play water sports;

          -  Dermography;

          -  Use of the following topical or systemic drugs: immunosuppressants, antihistamines,
             non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection
             or, considering deposit corticoids, the interval shall be 1 month prior to selection;

          -  Treatment with acid vitamin A and/or its derivatives via oral or topical until

             1 month before the beginning of the study;

          -  Aesthetic and/or body dermatological treatment until 3 weeks before selection;

          -  Vaccination during the study or until 3 weeks before the study;

          -  Being participated in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Phototoxic</mesh_term>
    <mesh_term>Dermatitis, Photoallergic</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

